Medtronic plc MDT continues to broaden portfolio with pain therapeutic solutions. Following the FDA approval, the company has recently made a significant breakthrough with the U.S. launch of the Intellis platform for management of certain types of chronic intractable pain.
Per Medtronic, this Intellis platform is able to overcome certain limitations related to current spinal cord stimulation (SCS) systems like battery performance. The platform can power the Evolve workflow, which standardizes guidance and balances high-dose (HD) and low-dose (LD) therapy settings.
Among other advancements of this platform, it is worth mentioning that it can be managed on the Samsung Galaxy Tab S2 tablet interface. This provides the physicians with faster delivery of evolving workflows and software upgrades. The Intellis platform includes both Medtronic’s proprietary SureScan MRI technology (for the broadest access available to MRI diagnostic imaging and simple eligibility determination) as well as AdaptiveStim technology (for automatic adjustments to deliver the right therapy dose to the right location as the pain target shifts according to body position).
Per a Transparency Market Research report, Global Pain Management Therapeutics Market is expected to ascend to $83 billion by 2024from $60.2 billion in 2015. Per Medtronic, back problems are one of the top 10 most expensive medical conditions with estimated 30% of the 300,000 patients annually undergoing lumbosacral spine procedures, which develop chronic intractable pain.
Keeping the above problem in mind, we are looking forward to a solid customer adoption of Intellis platform considering the huge and growing market for chronic pain management.
Medtronic PLC Price
Medtronic PLC Price | Medtronic PLC Quote
Over the last three months, Medtronic has underperformed the broader industry. The stock has lost 10.8% versus the 2.5% gain of the broader industry during the period.
Zacks Rank & Key Picks
Medtronic carries a Zacks Rank #4 (Sell).
Some better-ranked medical stocks are Edwards Lifesciences Corporation EW, Chemed Corporation CHE and Amedisys, Inc. AMED. Edwards Lifesciences sports a Zacks Rank #1 (Strong Buy), while Chemed and Amedisys carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has rallied roughly 19.5% over the last six months.
Chemed has a long-term expected earnings growth rate of 10%. The stock has gained 3.3% over the last six months.
Amedisys has a long-term expected earnings growth rate of 18.2%. The stock has gained 3.5% over the last six months.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure.
See these buy recommendations now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Medtronic PLC (MDT) : Free Stock Analysis Report
Edwards Lifesciences Corporation (EW) : Free Stock Analysis Report
Amedisys Inc (AMED) : Free Stock Analysis Report
Chemed Corp. (CHE) : Free Stock Analysis Report
To read this article on Zacks.com click here.